Doxapram in respiratory failure. A case presentation

The value of Doxapram in managing patients in respiratory failure due to an exacerbation of their chronic pulmonary disease is still not widely accepted. Controlled clinical trials are clearly necessary to determine whether Doxapram will improve the morbidity and mortality in these patients. However, it does seem that Doxapram is the most suitable of the respiratory stimulants available and this drug should be seriously considered when managing these difficult patients.